Literature DB >> 6741806

Factors influencing the one-year mortality of dilated cardiomyopathy.

D V Unverferth, R D Magorien, M L Moeschberger, P B Baker, J K Fetters, C V Leier.   

Abstract

This study was designed to determine prognostic risk indicators of nonischemic dilated cardiomyopathy (DC). Sixty-nine patients were studied. Each patient underwent physical examination (including a history), electrocardiography, echocardiography, cardiac catheterization, 24-hour monitoring and endomyocardial biopsy. The mortality rate at 1 year was 35% (24 deaths). Univariate analysis revealed that the most powerful predictor of prognosis was the left intraventricular conduction delay (p = 0.003). The pulmonary capillary wedge pressure was also predictive of mortality (p = 0.005). Other significant factors, in order of importance, were ventricular arrhythmias (p = 0.007), mean right atrial pressure (p = 0.008), angiographic ejection fraction (p = 0.03), atrial fibrillation or flutter (p = 0.01) and the presence of an S3 gallop (p = 0.05). Factors such as duration of symptoms, presence of mitral regurgitation, end-diastolic diameter, myocardial cell size and percent fibrosis in the biopsy and treatment with vasodilators, antiarrhythmic and anticoagulant drugs were not significant predictors. Multivariate analysis was used to determine which combination of factors could most accurately predict survival and death. The most important factors were left conduction delay, ventricular arrhythmias and mean right atrial pressure. An equation was derived that can be applied to the prognosis of patients with DC. Thus, the clinical assessment of patients with DC can accurately predict the probability of surviving or dying in 1 year.

Entities:  

Mesh:

Year:  1984        PMID: 6741806     DOI: 10.1016/0002-9149(84)90320-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  51 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 2.  Identification of patients at increased risk for potentially malignant arrhythmias.

Authors:  A J Moss
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 3.  Predicting survival in heart failure.

Authors:  Viorel G Florea; Inder S Anand
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

4.  Pacing polarity and left ventricular mechanical activation sequence in cardiac resynchronization therapy.

Authors:  Hyan Suk Yang; Giuseppe Caracciolo; Partho P Sengupta; Ramil Goel; Krishnaswamy Chandrasekaran; Komandoor Srivathsan
Journal:  J Interv Card Electrophysiol       Date:  2012-05-15       Impact factor: 1.900

Review 5.  Beta blockers in heart failure haemodynamics, clinical effects and modes of action.

Authors:  P A R de Milliano; J G P Tijssen; P A van Zwieten; K I Lie
Journal:  Neth Heart J       Date:  2001-11       Impact factor: 2.380

6.  Mortality in heart failure: clinical variables of prognostic value.

Authors:  J G Cleland; H J Dargie; I Ford
Journal:  Br Heart J       Date:  1987-12

7.  Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group.

Authors:  A Di Lenarda; G Secoli; A Perkan; D Gregori; G Lardieri; B Pinamonti; G Sinagra; M Zecchin; F Camerini
Journal:  Br Heart J       Date:  1994-12

8.  Long-term prognostic significance of M mode echocardiography in young men after myocardial infarction.

Authors:  S V Eriksson; K Caidahl; A Hamsten; U de Faire; N Rehnqvist; K Lindvall
Journal:  Br Heart J       Date:  1995-08

9.  Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy.

Authors:  K P Anderson; R Walker; P Urie; P R Ershler; R L Lux; S V Karwandee
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

10.  Sociology meets genetics: sociogenetic implications for future management of hypertension and heart failure.

Authors:  Randy Wexler; Adam Pleister; David Feldman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.